A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples